Inclusion Criteria:

          1. Provision of signed and dated informed consent prior to any study specific procedures,
             sampling or analyses.

          2. Aged at least 18 years old

          3. Patients must have a histologically proven diagnosis of glioblastoma/gliosarcoma

          4. Patients must have previous treatment including bevacizumab

          5. Patients must have a radiological diagnosis of recurrent/relapsed or progressive
             glioblastoma/gliosarcoma after bevacizumab including therapy according to response
             assessment in neuro-oncology (RANO) criteria

          6. At least one confirmed measurable lesion or non measurable lesion as determined by
             RANO criteria

          7. Patients must undergo IDH1 mutational testing on a tumor specimen before entering the
             study. Immunohistochemistry (IHC) is sufficient for enrollment, although DNA
             sequencing may also be performed as per local institutional guidelines. Patients are
             eligible regardless of their tumor status.

          8. Karnofsky Performance Status (KPS) ≥ 70

          9. A person who satisfies the following criteria in hematologic, renal, and hepatic
             function tests (1) Hematologic tests - Absolute neutrophil count (ANC) ≥ 1.5 x 109/L -
             Platelets ≥ 75 x 109/L

             - Hemoglobin ≥ 9.0 g/dL (2) Blood coagulation tests

             - Prothrombin time (PT) ≤ 1.5 x Upper limit of normal (ULN)

             - Activated partial thromboplastin Time (aPTT) ≤ 1.5 x ULN (3) Hepatic function tests

               -  Total bilirubin ≤ 1.5 x ULN

               -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 3 x ULN (4)
                  Renal function test

               -  Creatinine clearance (CrCl) ≥ 30 mL/minute calculated by Cockcroft-Gault formula

         10. Life expectancy of at least 12 weeks

         11. Females of child bearing potential must have a negative pregnancy test during
             screening and must not be breastfeeding or intending to become pregnant during the
             study.

         12. Male patients with female partners of child-bearing potential must be willing to use
             two forms of acceptable contraception, including one barrier method, during their
             participation in this study and for 16 weeks following the last dose of the study.
             Refer to section 10.5.1 Restrictions, permitted methods of contraception and
             definitions.

        Exclusion Criteria:

          1. Diagnosed with malignant tumors, except basal cell carcinoma, cutaneous squamous cell
             carcinoma, and noninvasive uterine cervical cancer treated within 2 years prior to
             receiving the first dose of treatment.

          2. The following concomitant diseases:

        (1) Uncontrolled hypertension (systolic blood pressure [SBP] > 150 or diastolic blood
        pressure [DBP] > 90 mmHg) (2) Uncontrolled seizures (3) Class III or IV heart failure
        according to New York Heart Association (NYHA) classification (4) Oxygen-dependent chronic
        disease (5) Active psychiatric disorder (schizophrenia, major depressive disorder, bipolar
        disorder etc.). Treated depression with ongoing antidepressant medication is not an
        exclusion.

        3) Not recovered from AEs < National Cancer Institute -Common Terminology Criteria for
        Adverse Events (NCI-CTCAE) grade 2 caused by CCRT 4) Treatment with bevacizumab including
        therapy 2 weeks prior to receiving the first dose of treatment.

        5) Undergone major surgery requiring general anesthesia or a respiratory assistance device
        within 4 weeks prior to the baseline visit (within 2 weeks for video-assisted thoracoscopic
        surgery [VATS] or open-and-closed [ONC] surgery) 6) Treated with other investigational
        products within 4 weeks prior to the patient receiving the first dose of treatment.

        7) A known history of severe drug hypersensitivity or hypersensitivity to a therapy similar
        to the study drug 8) Unable to participate in the trial according to the investigator's
        decision. 9) Patient not eligible for sequential MRI evaluations are not eligible for this
        study 10) Previous therapy with VEGF-targeted agents except bevacizumab. 11) Known active
        hepatitis B or hepatitis C infection 12) Has received a live vaccine within 30 days prior
        to enrollment. Seasonal flu vaccines that do not contain live virus are permitted.

        13) Has had a serious or non-healing wound, ulcer, or bone fracture within 28 days prior to
        enrollment